Mnv-201
Pearson Syndrome
Minovia Therapeutics Ltd.Cell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pearson Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epi-743 Edison Pharmaceuticals Inc | Phase 2 | CCC |
MNV-BLD Minovia Therapeutics Ltd. | Phase 1/2 | CCC |
Same molecule, other indications
Mnv-201 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →